IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

metrics 2024

Innovating Insights in Immunopharmacology and Toxicology

Introduction

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

Metrics 2024

SCIMAGO Journal Rank0.68
Journal Impact Factor2.90
Journal Impact Factor (5 years)3.20
H-Index61
Journal IF Without Self2.90
Eigen Factor0.00
Normal Eigen Factor0.45
Influence0.61
Immediacy Index0.80
Cited Half Life6.70
Citing Half Life6.50
JCI0.71
Total Documents1769
WOS Total Citations2870
SCIMAGO Total Citations8556
SCIMAGO SELF Citations317
Scopus Journal Rank0.68
Cites / Document (2 Years)3.18
Cites / Document (3 Years)3.31
Cites / Document (4 Years)3.16

Metrics History

Rank 2024

Scopus

Toxicology in Pharmacology, Toxicology and Pharmaceutics
Rank #58/133
Percentile 56.39
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #141/313
Percentile 54.95
Quartile Q2
Immunology and Allergy in Medicine
Rank #115/233
Percentile 50.64
Quartile Q2
Immunology in Immunology and Microbiology
Rank #133/236
Percentile 43.64
Quartile Q3

IF (Web Of Science)

IMMUNOLOGY
Rank 108/181
Percentile 40.60
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 147/354
Percentile 58.60
Quartile Q2
TOXICOLOGY
Rank 49/106
Percentile 54.20
Quartile Q2

JCI (Web Of Science)

IMMUNOLOGY
Rank 85/181
Percentile 53.04
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 162/354
Percentile 54.24
Quartile Q2
TOXICOLOGY
Rank 53/106
Percentile 50.00
Quartile Q3

Quartile History

Similar Journals

Cellular & Molecular Immunology

Charting New Territories in Immunological Science
Publisher: CHIN SOCIETY IMMUNOLOGYISSN: 1672-7681Frequency: 12 issues/year

Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

European Journal of Pharmacology

Shaping the future of pharmacology through impactful scholarship.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

VIRAL IMMUNOLOGY

Innovating research to combat viral infections through immunology.
Publisher: MARY ANN LIEBERT, INCISSN: 0882-8245Frequency: 10 issues/year

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Immunity Inflammation and Disease

Bridging gaps in understanding immune responses for a healthier future.
Publisher: WILEYISSN: Frequency: 12 issues/year

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

IMMUNOLOGIC RESEARCH

Illuminating Immune Responses for Better Health Outcomes
Publisher: SPRINGERISSN: 0257-277XFrequency: 6 issues/year

IMUNOLOGIC RESEARCH, published by Springer, is a prestigious journal dedicated to advancing the field of immunology. Since its inception in 1986, this journal has provided a vital platform for researchers, practitioners, and students to share groundbreaking studies and innovative findings that influence clinical and laboratory practices in immunology. With an impact factor that reflects its importance, being ranked in the Q2 category for the year 2023 and positioned at 98th out of 236 in Scopus rankings for Immunology, it is recognized among its peers for the quality of its publications. The journal emphasizes rigorous peer review and encourages submissions across a diverse range of topics including but not limited to immune responses, vaccine development, and disease mechanisms. Though it does not currently offer open access, its insightful articles remain crucial for professionals seeking to stay at the forefront of immunological research. Designed for a broad audience within the scientific community, IMMUNOLOGIC RESEARCH continues to foster discovery and discussion that shapes our understanding of immune function and its implications for health and disease.

Journal of Ginseng Research

Transforming Wellness with Ginseng Insights
Publisher: KOREAN SOC GINSENGISSN: 1226-8453Frequency: 4 issues/year

Journal of Ginseng Research is a leading peer-reviewed publication dedicated to advancing the scientific knowledge and understanding of ginseng and its myriad applications in health and wellness. Published by KOREAN SOC GINSENG and located in the Netherlands, this open-access journal has been a pivotal resource for researchers, professionals, and students since its inception. With an impactful H-index and prestigious rankings in various categories, including Q1 in Biochemistry, Genetics and Molecular Biology, Biotechnology, Complementary and Alternative Medicine, and Plant Science, the journal stands at the forefront of interdisciplinary research in medicinal plants. The Scopus rankings further enhance its reputation, highlighting its position as the leading journal in Complementary and Alternative Medicine and among the top resources in related fields. Spanning research from 2010 to 2024, it offers a valuable platform for disseminating innovative findings, thus playing an essential role in shaping future studies on ginseng and similar botanicals.

Molecular Therapy Oncolytics

Advancing Oncological Science for Global Impact
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Journal of Immunotoxicology

Advancing the Frontiers of Immunotoxicology
Publisher: TAYLOR & FRANCIS LTDISSN: 1547-691XFrequency: 1 issue/year

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

ACTA PHARMACOLOGICA SINICA

Unveiling Breakthroughs in Medicine and Pharmacology
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

Innate Immunity

Transforming Immunology for Healthier Futures
Publisher: SAGE PUBLICATIONS LTDISSN: 1753-4259Frequency: 6 issues/year

Innate Immunity, published by SAGE Publications Ltd, serves as a vital platform for disseminating cutting-edge research in the fields of immunology, microbiology, cell biology, and infectious diseases. With an ISSN of 1753-4259 and an E-ISSN of 1753-4267, this journal has been a prominent contributor to the academic community since its inception in 1996, focusing on the innate immune response and its implications for health and disease. Holding a respectable impact factor and categorized in the Q2 and Q3 quartiles across various relevant domains, Innate Immunity ranks competitively in major databases, including Scopus, where it appears in the top 75th percentile for Infectious Diseases. Researchers and professionals are encouraged to explore its wealth of articles that are pivotal in bridging fundamental immunology with clinical applications, fostering a deeper understanding of immune mechanisms vital for combating human diseases.